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Abstract Alzheimer’s disease (AD) is increasingly becoming
a major health problem throughout the US and Western Eu-
rope. As the remnants of the Baby Boom generation begin to
reach their seniority at the turn of the twenty-first century, the
disease has been unwillingly brought to the attention of the
public eye. A disease that has traditionally been associated
with an aging population has thus become a heated topic of
discussion as modern research attempts to prevent and treat
this major health burden and plague of the next decade.
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Introduction
In the field of Alzheimer’s research, there are currently two
contesting debates towards the causation of this hindering
disease. The first, also known as the amyloid cascade theory,
correlates the onset of Alzheimer’s to the deposition of an
abnormal protein called amyloid-beta (Aβ) and stands as the
most studied explanation of AD [1]. Those who support this
viewpoint have been known as Bbaptists.^
The second competing hypothesis, which is slowly gaining
more attention, associates the onset of Alzheimer’s disease
instead to fibrillary tangles called tau protein. Scientists in
support of this theory, the Btauists,^ are attempting to target
and block tau hyperphosphorylation in Alzheimer’s patients in
hopes of relieving the negative consequences of the disease.
New innovations, taking into account both perspectives,
are changing the field of Alzheimer’s research. Whereas be-
fore scientific endeavors sought to target the disease in its later
stages, now a more preventative approach is being undertaken
in hopes of stopping the onset of the disease altogether. In
support of either theory of AD, there is an overwhelming
consensus that Alzheimer’s disease can exist in two distinct
forms. These dichotomous variants consist of the more com-
mon late-onset Alzheimer’s (LOAD) and a more genetic form
called early-onset Alzheimer’s (EOAD). Current research
seeks to target either form in its earliest stages, even before
the very first symptomatic signs of deterioration appear [2].
The major risks for developing LOAD are the APOE
ε4 gene and aging. Individuals carrying both alleles of
this gene, as opposed to those who have the ε3 alleles,
have a 50 % greater risk of developing the disease [3, 4].
Researchers are also aware that individuals carrying both
ε2 alleles have a 50 % reduced risk of ever contracting
Alzheimer’s [3, 4]. There are, however, other non-genetic
predispositions towards the development of AD. These
risk factors include various environmental or epigenetic
stimulants like decreased hippocampal volume, being am-
yloid positive, or having a CSF marker for AD such as
low CSF Aβ and increased/phosphorylated tau protein
[2]. We also now recognize that there may be several
stages of the disease even before the development of
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AD is evident. Amyloid plaques may be seen in the
brains of 20–30 % of normal older individuals through
PET imaging and yet it may take years between an ab-
normal test and the development of AD [5]. Evidence
such as this confirms the existence of a pre-clinical form
of AD called mild cognitive impairment (MCI). Slowly,
the analysis of these abnormal CSF levels along with the
evolving use of PET imaging scans to detect amyloid
plaques are beginning to constitute the bio-markers for
the clinical diagnosis of MCI due to AD and thus helping
to provide the answers needed to halt the onset of demen-
tia in patients.
Current Research
Although medical treatment will be an important component
of AD management in the future, there are several encourag-
ing trends towards early preventative measures to reduce the
incidence of AD. Simple lifestyle changes such as 20 min of
daily exercise, a Mediterranean diet, and early diagnosis and
treatment of diabetes concurrent with low cholesterol levels all
help decrease the risk of AD. Keeping the brain mentally
active with tasks such as learning new languages, increased
social interaction, and other complex learning processes have
also been found to be essential remedies, which could aid in
the prevention of Alzheimer’s disease.
However, these preemptive strategies are not always
enough, especially for individuals who are genetically
predisposed to Alzheimer’s. Here, medical innovations
must take the lead instead, in hopes of relieving the strain
the disease causes to both the patient and their family
members. Yet although many drugs are currently in the
pipeline for AD, no drugs have been successfully ap-
proved in the EU and the USA in almost 15 years. Cur-
rent treatments available for Alzheimer’s disease in the
market consist mostly of cholinesterase inhibitors such
as donepezil, galantamine, and rivastigmine as well as
the NMDA receptor uncompetitive antagonist memantine
[2]. These drugs, which are commonly referred to as
symptomatic treatments, are only helpful for a limited
time span in improving the cognitive abilities of patients
with AD. Consequently, none of these drugs offer the
long-term answers we are currently seeking: finding true
disease modifiers. In light of this, the research being done
on the formation of amyloid β and/or neurofibrillary tan-
gles of tau protein aggregates is essential for finding a
more stable, long-term answer for the longevity as well
as mental and functional capabilities of individuals
afflicted with Alzheimer’s disease. In the near future, this
research will provide the answer to the cure and possible
early prevention of Alzheimer’s disease.
The Baptists’ Perspective
The Inhibitors The amyloid cascade theory has launched
several promising studies in the field of Alzheimer’s research,
focusing on the specific targeting of the formation and accu-
mulation of Aβ into amyloid plaques. The production of am-
yloid β plaques in patients with Alzheimer’s involves two
essential steps. The first step comprises of the cleavage of
the amyloid precursor protein (APP) by the beta-site amyloid
precursor protein-cleaving enzyme (BACE1/β-secretase), an
enzyme found only in Alzheimer’s patients, producing the
C99 fragment [6]. Concurrently, the next step involves the
cleavage of this C99 compound by γ-secretase, which leads
to the production of amyloid oligomers. The clumping togeth-
er of these amyloid β oligomers to form amyloid plaques can
then prevent cellular signaling at neuron synapses, causing
AD. It is important to note that in healthy individuals, the ∝–
secretase enzyme is used to cut APP instead of BACE1, sug-
gesting a strong correlation between elevated levels of the
BACE1 and late-onset Alzheimer’s in patients. To this end,
an array of novel strategies have begun to target directly/
indirectly the accumulation of Aβ deposits through the use
of monoclonal antibodies, antigens, beta and gamma secretase
inhibitors, and anti-amyloid aggregation compounds. The in-
hibition of γ-secretase or BACE1, two mechanisms essential
to the amyloid cascade theory, would thus, in theory, indirectly
prevent amyloid plaque buildup.
Among the new BACE1 inhibitors under active develop-
ment are the small molecules MK-8931 (Merck), AZD3293
(AstraZeneca/Lilly), E2609 (Eisai/Biogen), and JNJ
54869111 (Janssen). These new compounds are looking to
find the answers that their predecessors could not, since the
several gamma secretase inhibitors such as semagacestat
(Lilly), begacestat (Pfizer), and avagacestat (Bristol-Myers
Squibb) all failed in clinical studies and have thus been
discontinued.
MK-8931 (Merck)MK-8931, another BACE1 inhibitor [7•],
showed promising phase 1 results and is now currently enroll-
ing participants in their P3 trials to test the effect of the mol-
ecule on a larger sample size.
AZD3293 (AstraZeneca/Lilly) This BACE1 inhibitor is in a
late-stage BACE1 program that has produced good CSFAB
reduction in P1. The collaborative effort of both
AstraZeneca and Lilly wishes to target and prevent the
cleavage of the APP protein and subsequent release of the
C99 fragment by β-secretase. Both companies are looking
to combine the phase 2/3 trials for the drug, having a large
joint phase 2/3 trial called AMARANTH with over 1000
patients with MCI due to AD or mild AD [8].
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JNJ 54869111 (Janssen) Presently, there are several more
studies with promising results underway that may alter the
treatment of AD in the future. Among the BACE1 secretase
inhibitors, JNJ 54869111 has shown outstanding results as a
potent brain penetrant achieving up to 95 % Aβ reduction
with once daily oral dose [5]. Developed by Shionogi in Oc-
tober 2012, the drug hopes to investigate certain key features
such as subject engagement and responsiveness, and the ef-
fects, safety, and tolerability of multiple dosing [5]. JNJ
54869111 entered its first human dosing on April 2013 as
Shionogi aims to monitor the CSF Aβ output after a variety
of dosing regiments.
PQ912 (Probiodrug) This is a small molecule glutaminyl
cyclase (QC) inhibitor. QC catalyzes the formation of the
pyroglutamate-modified amyloid peptides [9], a phenomenon
most common in AD patients. Probiodrug’s PQ912 drug is
testing a novel implementation of QC inhibition as an indirect
method of Alzheimer’s prevention.
CAD106 (Novartis) Novartis is taking a slightly different
approach than its competitors as it plans to commence a trial
of CAD106, an active immunotherapy, and the BACE1 inhib-
itor NB360 in up to 1300 cognitively healthy ApoE4-positive
subjects [10•]. The purpose of the trial will be to determine
whether the prevention of amyloid plaque is possible, the
source baptists believe to be the cause of Alzheimer’s disease.
The trial, which will start enrollment for the CAD106 dosing
arm in late 2015, will be a decisive turning point in pin-
pointing the onset of AD and could possibly shift the ap-
proaches being used in Alzheimer’s research in favor of tau
inhibition mechanisms if the trials end in failure. Along with
CAD106, Novartis and its partner Banner Alzheimer’s Insti-
tute will commence enrollment for the NB360 dosing arm of
the study in 2016 [11••]. The implementation of NB360 in the
near future seems bright as clinical trials begin after its success
in reducing amyloid plaques in animal models [12•].
Monoclonal Antibodies in Action The potential for the treat-
ment of AD through the use of monoclonal antibodies is also
encouraging. These studies use a much more direct approach,
as monoclonal antibodies bind directly to amyloid protein to
prevent plaque buildup. Preclinical trials in transgenic mice
have shown that implementation of N-terminus-directed anti-
bodies against Aβ are able to effectively reduce the collection
of amyloid deposits in the brain [13, 14] With this break-
through, several monoclonal antibodies have begun to be test-
ed in clinical trials such as bapineuzumab, gantenerumab,
crenezumab, solanezumab, BAN2401, and aducanumab.
Many of these new studies are focused in targeting early pre-
vention in individuals at risk of AD due to familial and genetic
factors. These studies are thus attempting to use the lag be-
tween the early formation of amyloid plaques and clinically
diagnosed MCI, to attack the early onset of the disease
preemptively.
Bapineuzumab (Pfizer/Janssen Alzheimer Immunothera-
py) A humanized monoclonal antibody that is capable of
binding to both soluble and fibrillar forms of Aβ [2]. Unfor-
tunately, the clinical trials involving the phase 3 of the drug
ended in disappointment, as the drug failed to show any effi-
cacy in improving the cognitive abilities of patients afflicted
with mild to moderate Alzheimer’s. Nevertheless, the connec-
tion between bapineuzumab and the lowering of p-tau, a CSF
marker of neurological degradation, in both APOE ε4 gene
individuals and those without the gene, provided an encour-
aging start to new research involving MCI due to prodromal/
mild AD [2].
Gantenerumab (Roche) Following the failure and early ter-
mination of the gantenerumab phase 3 SCarlet RoAD trial in
prodromal AD, Roche has decided to continue the P3 Mar-
guerite Road trial for mild AD. The SCarlet RoAD trial had
originally terminated after a failed futility analysis, which
evaluated half (n=400) of the trial population after 2 years
on treatment [15•]. The P3Marguerite Road trial shows prom-
ising results with some considerations at increasing the dosage
of participants.
Crenezumab (Roche/Genentech) Beginning in late February
2015, Roche initiated another Alzheimer’s trial with the drug
crenezumab, another monoclonal antibody targeting amyloid
plaque buildup [16]. A small P1b trial of the Crenezumab IV
formulation was underway with the aim to determine whether
(and to what extent) the IV dose can be increased for potential
evaluation in future P2 or P3 trials. Recently, Roche has
launched the phase 2 trials, with participants receiving
15 mg/kg per month of the drug [16]. The phase 2 trials,
targeting patients with mild to moderate Alzheimer’s, are ex-
pected to be ongoing until the year 2020 [16].
Solanezumab (Lilly) Another study is taking a novel ap-
proach by testing clinically normal individuals who have beta
amyloid PET scans in a randomized clinical trial in conjunc-
tion with the Eli Lilly monoclonal antibody solanezumab [17].
Solanezumab had previously launched two phase 3 trials (EX-
PEDITION 1 and EXPEDITION 2) [18]. However, the drug
failed to improve overall cognitive and memory abilities in
patients significant slowing of cognitive decline; the pre-
specified analysis of patients with mild AD did show a slight
signal of improvement. Hence, Lilly initiated EXPEDITION
3 in a mild AD only population. This ongoing trial, which just
completed enrollment in April/May 2015, involves partici-
pants who are all amyloid positive on a florbetapir PET scan;
in theory, improving the likelihood of success for
solanezumab in EXPEDITION 3.
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BAN2401 (Eisai/BioArctic/Biogen) Eisai and BioArctic’s
BAN2401 drug is currently undergoing phase 2 clinical trials,
after a successful phase 1 run [19••]. Many are hopeful for the
future indications of this drug, which can serve as a selective
immunotherapy technique against AD if it achieves to suc-
cessfully bind and neutralize the neurodegenerative amyloid
protein formation found in patients with dementia. Even more
exciting is Eisai’s employment of the innovative Bayesian
trial. The Bayesian design will allow for the potential early
termination of the P2 trials before full enrollment if either of
two criteria are met: strong efficacy signals of the drug
(allowing advancement to P3) or interim futility (allowing
discontinuation of the program and thus reduction in R&D
investment) [20].
Aducanumab (Biogen) Aducanumab, an anti beta-amyloid
monoclonal antibody, is yet another study being conducted in
subjects with prodromal or mild AD. At the recent ADPD
2015 conference in Nice, Biogen Idec presented a positive
phase 1a study with a statistically significant reduction of
amyloid plaques as measured by PET imaging after 1 year
as well as a significant decline on Clinical Dementia Rating
Sum of Boxes (CDR-SB) in the first year of treatment. Some
of these findings helped to renew optimism for the amyloid
hypothesis, which was losing acceptance after several years of
negative results. There was also a high incidence of amyloid-
related imaging abnormalities/microhemorrhages (ARIA-E),
which was dose dependent and more common in the ApoE4+
subjects [5]. ARIA tended to start early, was generally mild
and transient, and a majority of patients continued treatment
with a lower dose of aducanumab (BIIB-037).
DIAN Initiative An initiative called DIAN (Dominantly
Inherited Alzheimer Network) is conducting a multitude of
studies on families with dominant genetic mutations [21].
The DIAN studies show an international effort of attempting
to make future AD medication accessible for persons of all
nationalities.
Alzheimer’s Prevention Initiative (API) Another study led
by the Alzheimer’s Prevention Initiative has been launched
with a focused attention to a section of the Colombian popu-
lation. These trials involve Colombian families with Basque
ancestry from the Antioquia region, like the Cuartas family,
which have developed cases of EOAD [22, 23]. These Co-
lombian families are affected by a presenilin I genetic muta-
tion which will cause the development of Alzheimer’s disease
to all the offspring which inherit this mutated gene.
ADCS-A4 trial Yet another collaborative effort in the field of
Alzheimer’s, the A4 trials are focusing their efforts at analyz-
ing the effect solenezumab will have on 1150 adults who are
all amyloid positive but have yet to show signs of cognitive
impairment [24•]. The project, which began in 2014, is cur-
rently running phase III trials and looking forward to a possi-
ble 2-year extension in the near future [23].
TOMORROW Trial Along with the previous three pro-
grams mentioned above (DIAN, API, ADCS-A4), the TO-
MORROW trials represent the Collaboration for Alzheimer’s
Prevention (CAP). The TOMORROW trial is researching the
effects that low-dose pioglitazone will have in patients with
the TOMM40 genetic mutation, a mutation that heightens the
possibility for neurogenesis and the onset of MCI due to AD
[25].
Limitations and Future Directions of Amyloid PET
in Clinical Practice
Amyloid imaging with PET scans has allowed for more con-
fident diagnosis of AD and is being used muchmore frequent-
ly in clinical trials. The PET imaging scans can easily detect
the presence of Aβ in the brain. Currently, most of the studies
involving the amyloid cascade theory make strategic use of
PET scans in the determination of possible research partici-
pants. These amyloid PET scans have thus become a recent
commodity in the diagnosis of possible AD onset in research
subjects. Following the success of this early diagnosis, tau
tracers are also currently under development. However, while
amyloid PET scans are becoming an invaluable research and
diagnosis tool, several improvements and impediments still
exist. While the beneficial outcomes of PET have been a
clear-cut distinction in clinical trials, US Medicare does not
yet cover its full cost of $3500 for diagnostic practices [5]. If
amyloid PET scans become more common in the diagnosis of
AD in patients not participating in clinical trials, then they
need to become more cost effective as well. Moreover, the
implementation of more quantitative measures would be a
strong asset as the PET scans currently only indicate if an
individual is amyloid positive or negative. More prognostic
data, such as a percentage measurement of an individual’s
amyloid plaque burden, can be a helpful tool in future research
initiatives. However, the biggest impediment with the success
of amyloid PET scans seems to be the lack of effective thera-
peutic intervention. Even if patients test amyloid positive, we
currently lack the instrumentations necessary to implement the
appropriate follow-up treatments to stop the neurodegenera-
tive progression of the disease.
The Tauist Outlook
Hyperphosphorylation of a microtubule-associated protein
known as tau leads to the formation of neurofibrillary tangles
in neurons. Neurofibrillary tangles aggregate, or group, in an
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insoluble form in neurons affecting normal neuronal func-
tions. Several molecules are involved in the phosphorylation
of tau including the kinases namely the glycogen synthase
kinases (GSK-3) and cyclin-dependent protein kinase
(CDK). While studies involving these molecules are further
behind those that target the amyloid cascade theory, there have
been some promising starts with compounds aimed at
inhibiting the tau pathways in novel ways. Several compounds
have been developed such as valproate, lithium, and Methy-
lene blue [26]. Other innovative efforts have also begun in the
development of anti-tau vaccines.
Methylene Blue in Perspective Of all the tau targeting com-
pounds, Methylene blue seems to have the most promising
results. The compound, which is a type of phenothiazine,
has been shown to reduce tau aggression in transgenic mice.
The trial, using P301L tau transgenic mice, gave several oral
administrations of Methylene blue for 5 months to test the
effects of the compound in vivo [27]. The results were suc-
cessful, depicting a tau aggression decrease in the mice, giving
the scientific community high hopes of using the compound in
future human trials for the possible treatment of AD via anti-
tau phosphorylation. With these results in mind, TauRx Phar-
maceuticals recently announced the completion of their phase
II clinical trials involving the testing of this Methylene Blue
compound in a sample size of 321 adults afflicted with mild/
moderate AD [28].
ACI-35 (AC Immune/Janssen) ACI-35 is one of the first
drugs of its kind. Developed through the AC Immune pro-
gram, this compound is a pioneer anti-tau vaccine currently
in phase 1b. Researchers hope the vaccine will help stimulate
the patients’ immune systems against misfolded and phos-
phorylated tau proteins involved in the onset of Alzheimer’s
[29].
AADvac1 (AXONNeuroscience) In 2013, AXONNeurosci-
ence’s AADvac1 began its first P1 trials for another vaccine
targeting anti-tau phosphorylation. AADvac1 consists of syn-
thetic polypeptides, which are meant to elicit an immune re-
sponse against pathogenic tau proteins [30•].
Conclusion
Moving forward, we recognize that, potentially, single agents
will not be effective in the treatment of Alzheimer’s disease.
Instead, the answers sought in this multifactorial disease in-
volving multiple pathways and pathologies can be found in a
combination of clinical methodologies and discoveries. The
more we fail at single protein-targeted therapies, the more we
lean towards a belief that AD is a heterogenic, complex dis-
order with deregulation of multiple pathways due to genetic,
epigenetic, and environmental reasons. Hence, AD needs to
be approached using a systems biology/genomic/
transcriptomic/proteomic method to get a more comprehen-
sive picture of the cause, effect, and treatment options. Com-
binational therapies targeting both Aβ accumulation and tau
protein malformation may just be the answer so sought after
for AD research. Already, PET imaging has given both re-
searchers and physicians a more viable way towards the diag-
nosis of Alzheimer’s. As future studies are concluded and
more information is gathered, the efficacy of Alzheimer’s
treatment will be greatly improved.
The epidemic of AD is near at hand. Unfortunately, to date,
no new compounds have achieved FDA or EMA approval in
the last decade and a half. The stakes are high for a drug to
cross this barrier. Several hundred compounds are now under
development and almost 200 trials on the way. The scientific
and pharmaceutical industries are aligned with millions of
dollars being poured into AD research. The scientific knowl-
edge has made significant progress and we may look forward
to breakthroughs in the next decade.
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